A5007744230- Cancer Genomics and Diagnostics
- Gene expression and cancer classification
- Cancer Cells and Metastasis
- Breast Cancer Treatment Studies
- Bioinformatics and Genomic Networks
- Molecular Biology Techniques and Applications
- Epigenetics and DNA Methylation
- Cancer-related molecular mechanisms research
- Monoclonal and Polyclonal Antibodies Research
- Insects and Parasite Interactions
- Ovarian cancer diagnosis and treatment
- Glycosylation and Glycoproteins Research
- Advanced Biosensing Techniques and Applications
- BRCA gene mutations in cancer
- Genomic variations and chromosomal abnormalities
- Angiogenesis and VEGF in Cancer
- MicroRNA in disease regulation
- HER2/EGFR in Cancer Research
- Circular RNAs in diseases
- Uterine Myomas and Treatments
- Axon Guidance and Neuronal Signaling
Royal Hospital
2019-2025
University of Leeds
2019-2020
Leeds Teaching Hospitals NHS Trust
2019
Albany College of Pharmacy and Health Sciences
2013
poor prognosis primary breast cancers are typically treated with cytotoxic chemotherapy. However, recurrences remain relatively common even after this aggressive therapy. Comparison of matched tumours pre- and post-chemotherapy can allow identification molecular characteristics therapy resistance thereby potentially aid discovery novel predictive markers or targets for chemosensitisation. Through comparison, we aimed to identify microRNAs associated chemoresistance, define microRNA target...
Abstract Poor-prognosis breast cancers are treated with cytotoxic chemotherapy, but often without any guidance from therapy predictive markers because universally accepted not currently available. Treatment failure, in the form of recurrences, is relatively common. We aimed to identify chemotherapy and resistance pathways cancer. Our hypothesis was that tumor cells remaining after neoadjuvant (NAC) contain somatic variants causing resistance, while present pre-NAC lost post-NAC cause...
Abstract Purpose More than a third of primary breast cancer patients are treated with cytotoxic chemotherapy, typically without guidance from predictive markers. Increased use neoadjuvant chemotherapy provides opportunities for identification molecules associated treatment response, by comparing matched tumour samples before and after therapy. Our hypothesis was that somatic variants increased prevalence therapy promote resistance, while reduced cause sensitivity. Methods We performed...
Abstract Background Breast cancer stem cells (BCSCs) are drivers of therapy-resistance, therefore responsible for poor survival. Molecular signatures BCSCs from primary cancers remain undefined. Here, we identify the consistent transcriptome shared across breast subtypes, and examine clinical relevance ITGA7, one genes differentially expressed in BCSCs. Methods Primary were assessed using immunohistochemistry fluorescently labelled Aldefluor ( n = 17). Transcriptomes sorted matched non-stem...
High prevalence of early-onset breast cancer (EOBC) has been reported in Middle Eastern populations. For example, Oman more than 50% patients with (BC) are under age 45 at diagnosis. Causes for this high incidence unknown. Germline BRCA gene mutations have associated EOBC, however, these and how they relate to EOBC not assessed.
Abstract Breast cancer is a heterogeneous disease and accumulating evidence suggests that treatment failure may be driven by intra-tumour heterogeneity (ITH). Utilising the current protocol for neoadjuvant (pre-surgery) chemotherapy (NAC) provides opportunity to study molecular genetic changes between pre- post-therapy assessing pre-therapy biopsies surgical resections. Whole exome sequencing was performed on matched post-treatment cells from 6 patients with oestrogen receptor positive...
<div>Abstract<p>Poor-prognosis breast cancers are treated with cytotoxic chemotherapy, but often without any guidance from therapy predictive markers because universally accepted not currently available. Treatment failure, in the form of recurrences, is relatively common. We aimed to identify chemotherapy and resistance pathways cancer. Our hypothesis was that tumor cells remaining after neoadjuvant (NAC) contain somatic variants causing resistance, while present pre-NAC lost...
<p>Somatic variants data</p>
<p>Supplementary information concerning: laser capture microscopy (Fig S1), efficiency of siRNA knock-down S2), results for ABC gene expression and function S3), abilities MUC17 PCNX1 to define patient outcomes S4), characteristics (Table sequencing metrics statistical parameters (Tables S4 S5) supplementary methods.</p>
<div>Abstract<p>Poor-prognosis breast cancers are treated with cytotoxic chemotherapy, but often without any guidance from therapy predictive markers because universally accepted not currently available. Treatment failure, in the form of recurrences, is relatively common. We aimed to identify chemotherapy and resistance pathways cancer. Our hypothesis was that tumor cells remaining after neoadjuvant (NAC) contain somatic variants causing resistance, while present pre-NAC lost...
<p>Supplementary information concerning: laser capture microscopy (Fig S1), efficiency of siRNA knock-down S2), results for ABC gene expression and function S3), abilities MUC17 PCNX1 to define patient outcomes S4), characteristics (Table sequencing metrics statistical parameters (Tables S4 S5) supplementary methods.</p>
<p>Somatic variants data</p>
Abstract Aims Chemoresistance is a key barrier to breast cancer cures, particularly in the triple-negative subtype. Mucins are O-glycosylated proteins that may drive therapeutic resistance and oncogenic progression carcinomas. Somatic mutations mucin 3 (MUC3), 12 (MUC12) 16 (MUC16) have been identified tumour samples, however their impacts on chemoresponse poorly explored. We aimed explore whether cell expression of transmembrane mucins MUC3, MUC12 MUC16 correlates with chemotherapy...